Literature DB >> 11117494

Immunohistochemical localization of the P2Y1 purinergic receptor in Alzheimer's disease.

D Moore1, S Iritani, J Chambers, P Emson.   

Abstract

The biological actions of extracellular nucleotides are mediated by two distinct classes of P2 receptor, P2X and P2Y. The G protein-coupled P2Y receptors comprise five mammalian subtypes, P2Y(1-11). The P2Y1 subtype is expressed abundantly throughout the human brain and is specifically localized to neuronal structures. In the present study, the distribution of the P2Y1 receptor was investigated in Alzheimer's disease (AD) brains. In contrast to control human brain, the P2Y1 receptor was localized to a number of characteristic AD structures such as neurofibrillary tangles, neuritic plaques and neuropil threads. Immunoblot analysis showed that this specific immunostaining observed over tangles was not a result of cross-reactivity between the anti-P2Y1 antiserum and abnormal tau protein, the major constituent of tangles. The significance of this altered P2Y1 cellular distribution in AD brains is at present unclear.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11117494     DOI: 10.1097/00001756-200011270-00041

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  20 in total

1.  Adenine nucleotide analogues locked in a Northern methanocarba conformation: enhanced stability and potency as P2Y(1) receptor agonists.

Authors:  R Gnana Ravi; Hak Sung Kim; Jörg Servos; Herbert Zimmermann; Kyeong Lee; Savitri Maddileti; José L Boyer; T Kendall Harden; Kenneth A Jacobson
Journal:  J Med Chem       Date:  2002-05-09       Impact factor: 7.446

Review 2.  International Union of Pharmacology LVIII: update on the P2Y G protein-coupled nucleotide receptors: from molecular mechanisms and pathophysiology to therapy.

Authors:  Maria P Abbracchio; Geoffrey Burnstock; Jean-Marie Boeynaems; Eric A Barnard; José L Boyer; Charles Kennedy; Gillian E Knight; Marta Fumagalli; Christian Gachet; Kenneth A Jacobson; Gary A Weisman
Journal:  Pharmacol Rev       Date:  2006-09       Impact factor: 25.468

Review 3.  P2Y receptors in the mammalian nervous system: pharmacology, ligands and therapeutic potential.

Authors:  Gary A Weisman; Lucas T Woods; Laurie Erb; Cheikh I Seye
Journal:  CNS Neurol Disord Drug Targets       Date:  2012-09       Impact factor: 4.388

Review 4.  Purinergic receptors as potential therapeutic targets in Alzheimer's disease.

Authors:  Lucas T Woods; Deepa Ajit; Jean M Camden; Laurie Erb; Gary A Weisman
Journal:  Neuropharmacology       Date:  2015-10-28       Impact factor: 5.250

5.  Astrocytic P2Y(1) receptor is involved in the regulation of cytokine/chemokine transcription and cerebral damage in a rat model of cerebral ischemia.

Authors:  Kazuya Kuboyama; Hideki Harada; Hidetoshi Tozaki-Saitoh; Makoto Tsuda; Kazuo Ushijima; Kazuhide Inoue
Journal:  J Cereb Blood Flow Metab       Date:  2011-04-13       Impact factor: 6.200

Review 6.  P2 receptors and neuronal injury.

Authors:  Heike Franke; Ute Krügel; Peter Illes
Journal:  Pflugers Arch       Date:  2006-04-28       Impact factor: 3.657

Review 7.  Pathophysiology of astroglial purinergic signalling.

Authors:  Heike Franke; Alexei Verkhratsky; Geoffrey Burnstock; Peter Illes
Journal:  Purinergic Signal       Date:  2012-05-01       Impact factor: 3.765

Review 8.  P2Y receptors in Alzheimer's disease.

Authors:  Laurie Erb; Chen Cao; Deepa Ajit; Gary A Weisman
Journal:  Biol Cell       Date:  2014-10-13       Impact factor: 4.458

9.  Selective loss of P2Y2 nucleotide receptor immunoreactivity is associated with Alzheimer's disease neuropathology.

Authors:  Mitchell K P Lai; Michelle G K Tan; Sara Kirvell; Carl Hobbs; Jasinda Lee; Margaret M Esiri; Christopher P Chen; Paul T Francis
Journal:  J Neural Transm (Vienna)       Date:  2008-05-28       Impact factor: 3.575

10.  Enhanced P2Y1 receptor expression in the brain after sensitisation with d-amphetamine.

Authors:  Heike Franke; Holger Kittner; Jens Grosche; Peter Illes
Journal:  Psychopharmacology (Berl)       Date:  2003-03-22       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.